Jason R Westin
Overview
Explore the profile of Jason R Westin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
7417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian Y, Budka J, Locke F, Westin J, To C, Tiwari G, et al.
Front Oncol
. 2025 Mar;
15:1519473.
PMID: 40083872
Introduction: CAR T cell therapy provided transformative outcomes for patients with B-cell lymphoma; however, a large fraction of patients remains at risk for relapse, underlying the need to uncover mechanisms...
2.
Manzar G, Pinnix C, Dudzinski S, Marqueen K, Cha E, Nasr L, et al.
Front Immunol
. 2025 Feb;
16:1517348.
PMID: 39958356
Background: Select patients with relapsed/refractory aggressive B cell lymphoma may benefit from bridging radiation (bRT) prior to anti-CD19-directed chimeric antigen receptor T cell therapy (CAR-T). Here, we examined patient and...
3.
Westin J, Phillips T, Mehta A, Hoffmann M, Gonzalez-Barca E, Thieblemont C, et al.
Blood Adv
. 2025 Feb;
PMID: 39908481
This Phase II study evaluated mosunetuzumab plus cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin (Pola-M-CHP) versus Pola-rituximab (R)-CHP for first-line treatment of diffuse large B-cell lymphoma (DLBCL). Patients were randomized 2:1...
4.
Chihara D, Steiner R, Nair R, Feng L, Ahmed S, Strati P, et al.
Blood Adv
. 2025 Feb;
PMID: 39908461
Treatment options are limited for both relapsed/refractory primary and secondary central nervous system (CNS) lymphoma and the prognosis remains poor. Prior studies have shown the activity of Bruton tyrosine kinase...
5.
Locke F, Westin J, To C
Future Oncol
. 2025 Jan;
21(4):393-407.
PMID: 39800964
No abstract available.
6.
Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert M, et al.
Blood
. 2024 Oct;
145(8):823-839.
PMID: 39441941
Antibiotic (ABX)-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. In...
7.
Manzar G, Wu S, Dudzinski S, Cha E, Yoder A, Corrigan K, et al.
Int J Radiat Oncol Biol Phys
. 2024 Sep;
121(4):1011-1025.
PMID: 39303997
Purpose: The impact of bridging radiation therapy (bRT) for chimeric antigen receptor (CAR) T-cell therapy on absolute lymphocyte count (ALC) kinetics and treatment outcome is unknown. Methods And Materials: We...
8.
Gurumurthi A, Chin C, Feng L, Fowler N, Strati P, Hagemeister F, et al.
EClinicalMedicine
. 2024 Aug;
74:102747.
PMID: 39161543
Background: Rituximab and lenalidomide is a preferred option for relapsed indolent B cell non-Hodgkin lymphoma. Obinutuzumab may be a superior combination partner with lenalidomide given enhanced antibody dependent cellular cytotoxicity...
9.
Ghobadi A, Munoz J, Westin J, Locke F, Miklos D, Rapoport A, et al.
Blood Adv
. 2024 Feb;
8(11):2982-2990.
PMID: 38315832
The optimal management of patients with relapsed/refractory large B-cell lymphoma (LBCL) after disease progression or lack of response to second-line (2L) therapy remains unclear. Here, we report outcomes among patients...
10.
Davis R, Westin J
Science
. 2024 Feb;
383(6682):480-481.
PMID: 38301021
Redirecting targeted proteins for degradation can overcome acquired drug resistance.